Onward Medical (ENXTBR:ONWD) Stock Rich Valuation Clashes With Deepening Losses

Onward Medical walked into this earnings day with a warm tailwind. The stock had gained about 20% over the past month and more than 15% across the last week, so expectations were already elevated.

The headline from the release is simple and emotional. The company is still burning cash hard, with a net loss of €24.7m in the first half of 2026, while the share price reflects a rich story stock on a steep price to sales multiple of 23.1x. That clash between heavy losses and lofty valuation is what is really driving sentiment today.

If you are interested in the story behind Onward Medical but uneasy about significant losses alongside a high price-to-sales (P/S) multiple, consider exploring 617 high quality undiscovered gems

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €4.2 million vs. €1.185 million (very large increase, roughly 3.5x higher)
• Net Loss (H1 2026 vs. H1 2025): loss of €24.7 million vs. loss of €21.178 million (loss widened by about 17%)
• Basic EPS (H2 2025 vs. H1 2025, trailing most recent EPS data): loss of €0.4231 per share vs. loss of €0.4744 per share (per share loss narrowed by about 11%)
• Gross Margin (H1 2026): approximately 70% on €4.2 million revenue, with gross profit of about €2.9 million

Prefer clean, visual charts over dense walls of earnings tables and footnotes? View Onward Medical's full financial picture and get a clear view of its valuation story in the company report for Onward Medical.

Onward Medical bulls focus on commercial milestones

Bullish investors argue that Onward Medical is transitioning from a pure R&D story into a real commercial neuromodulation platform, led by ARC EX. H1 revenue of €4.2m, with roughly €3.4m from products and a gross margin near 70%, lines up with that claim. So does the installed base. Around 150 clinics now run the system, with about 35% to 40% of U.S. spinal cord injury facilities already penetrated after six quarters. VA traction looks important rather than cosmetic, with presence in about half of VA hubs and a conversion rate above 90% from paid evaluations to purchases. Early home use is not just a slide headline either, since the company is selling more home units than clinic systems. The EMPOWER BP pivotal program is enrolling, which keeps the second indication narrative intact, even if revenue from it is still distant.

Bear case stresses cash burn and execution risk

Skeptics argue that heavy cash use, reimbursement uncertainty and a long ARC IM timeline could outweigh ARC EX progress. The H1 net loss of €24.7m and operating expenses of €26.3m confirm that the business is still highly loss making. Management has extended cash runway to Q1 2028 with €81.5m on hand, a €40.6m equity raise and access to a €50m debt facility, yet explicitly gives no breakeven timetable. That supports the worry about future dilution if growth slows. Reimbursement risk is not resolved either. CMS coding is only at application stage with a decision expected in Q4 2026, while current access leans on case by case support and VA channels. On the pipeline, EMPOWER BP is moving, but pivotal data are only expected in early 2027 and launch is targeted for 2029, which matches bears’ concern about a long gap before a second revenue driver arrives.

After a year of shareholder dilution, mounting losses and a long runway before breakeven, it is worth asking whether visible issues are masking deeper structural problems in Onward Medical. Review the independent risk analysis for Onward Medical which shows 2 important warning signs

Own Your Next Move

If Onward Medical's mix of rapid revenue growth and heavy losses has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for an entry point that fits your plan. Once you hold the shares, use the Portfolio Command Center to cut through noise and focus on key developments that truly affect your thesis. For longer term conviction building, turn to the Community to see how other investors are interpreting the same numbers and milestones. By surfacing hidden catalysts and risks early, you give yourself a better chance of staying ahead of the market rather than reacting to it late.

Seeking Alternatives Beyond Onward Medical?

Fresh ideas move first. Stocks with real momentum can be flying before most investors even notice them, so use curated screeners while it matters and get in early.

• Scan for resilient dividend payers that keep cash coming in even when sentiment cools by reviewing the 169 dividend fortresses before yields get caught dropping.
• Track fast moving AI opportunities that already generate profits instead of just burning cash by checking the curated 74 profitable AI stocks that aren't just burning cash while they remain under the radar for now.
• Target stronger balance sheets and steadier fundamentals so a single earnings miss does not derail your plan by using the list of solid balance sheet and fundamentals stocks (193 results) before the crowd piles in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com